Stay updated on Pembrolizumab and TKI in CML MRD Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.

Latest updates to the Pembrolizumab and TKI in CML MRD Clinical Trial page
- Check2 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing Revision: v3.5.3. This indicates a small update to the page's version label rather than substantive content changes.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page's revision tag was updated to v3.5.3, replacing v3.5.2. This represents an internal metadata update with no changes to the study details or visible content.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedRevision: v3.5.2 has been added, replacing the previous Revision: v3.5.0 on the page.SummaryDifference0.0%

- Check38 days agoChange DetectedNew update dates (e.g., 2026-04-03, 2026-03-31) were added and older dates (e.g., 2026-03-02, 2026-02-27, 2026-02) were removed from the study record.SummaryDifference0.1%

- Check45 days agoChange DetectedNo additions or deletions are visible in the provided data; the page appears unchanged.SummaryDifference0.0%

- Check52 days agoChange DetectedScreenshot comparison shows no content additions or deletions to core study information. The visible sections appear unchanged, including the brief summary, objectives, and eligibility criteria.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab and TKI in CML MRD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.